Immunogenicity of recombinant human interleukin-3.
Most recombinant human (rh) proteins elicit an immune response in experimental animals. Antibodies are usually detected within 1 to 2 weeks of protein administration. The immunogenicity of rh proteins is an important aspect for both experimental and clinical investigations. The formation of neutralizing antibodies-as shown here for rhIL-3-reduced the absolute bioavailability of the protein in Rhesus monkeys.
Gunn
H
H
Sandoz Pharma, East Hanover, New Jersey, USA.
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D000917:Antibody Formation; D001682:Biological Availability; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007377:Interleukin-3 / Q000276:immunology*; D008253:Macaca mulatta / Q000276:immunology; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000276:immunology
D000906:Antibodies; D007377:Interleukin-3; D011994:Recombinant Proteins